

## **Tafluprost Formulation**

| Vers<br>3.2 | sion                                  | Revision Date:<br>2024/09/28 |       | S Number:<br>8021-00016             | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15 |  |  |  |
|-------------|---------------------------------------|------------------------------|-------|-------------------------------------|---|--|--|--|
|             |                                       |                              |       |                                     |   |  |  |  |
| 1. P        | 1. PRODUCT AND COMPANY IDENTIFICATION |                              |       |                                     |   |  |  |  |
|             | Produc                                | t name                       | :     | Tafluprost Formu                    | Ilation   |  |  |  |
|             | Manufa                                | acturer or supplier's d      | letai | ls                                  |   |  |  |  |
|             | Compa                                 | ny                           | :     | MSD                                 |   |  |  |  |
|             | Addres                                | S                            | :     | 126 E. Lincoln Av<br>Rahway, New Je | venue<br>rsey U.S.A. 07065  |  |  |  |
|             | Teleph                                | one                          | :     | 908-740-4000                        |   |  |  |  |
|             | Emerge                                | ency telephone number        | · :   | 1-908-423-6000                      |   |  |  |  |
|             | E-mail                                | address                      | :     | EHSDATASTEW                         | /ARD@msd.com  |  |  |  |
|             | Recom                                 | mended use of the ch         | nem   | ical and restriction                | ons on use  |  |  |  |
|             |                                       | mended use<br>tions on use   | :     | Pharmaceutical<br>Not applicable    |   |  |  |  |

### 2. HAZARDS IDENTIFICATION

### **GHS Classification**

Not a hazardous substance or mixture.

### **GHS** label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

### Other hazards which do not result in classification

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

| Chemical name | CAS-No.     | Concentration (% w/w) |
|---------------|-------------|-----------------------|
| Tafluprost    | 209860-87-7 | >= 0.0003 -< 0.0025   |

### 4. FIRST AID MEASURES

| If inhaled              | : | If inhaled, remove to fresh air.          |
|-------------------------|---|---|
|                         |   | Get medical attention if symptoms occur.  |
| In case of skin contact | : | Wash with water and soap as a precaution. |



## **Tafluprost Formulation**

| D0016 Date of first issue: 2016/03/15  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
| nedical attention if symptoms occur.<br>n eyes with water as a precaution.<br>nedical attention if irritation develops and persists.<br>allowed, DO NOT induce vomiting.<br>nedical attention if symptoms occur.               |  |  |  |  |
| e mouth thoroughly with water.<br>e known.   |  |  |  |  |
| No special precautions are necessary for first aid responders.<br>Treat symptomatically and supportively.  |  |  |  |  |
|  |  |  |  |  |
| er spray<br>hol-resistant foam<br>on dioxide (CO2)<br>chemical   |  |  |  |  |
| e known.   |  |  |  |  |
| sure to combustion products may be a hazard to health.   |  |  |  |  |
| on oxides  |  |  |  |  |
| extinguishing measures that are appropriate to local cir-<br>stances and the surrounding environment.<br>water spray to cool unopened containers.<br>ove undamaged containers from fire area if it is safe to do<br>uate area. |  |  |  |  |
| r self-contained breathing apparatus for firefighting if nec-<br>ry.<br>personal protective equipment.   |  |  |  |  |
| o<br>u<br>r<br>ry  |  |  |  |  |

## Personal precautions protec- · Follow safe hand

| Personal precautions, protec-<br>tive equipment and emer-<br>gency procedures | : | Follow safe handling advice (see section 7) and personal pro-<br>tective equipment recommendations (see section 8).  |
|---|---|--|
| Environmental precautions   | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Prevent spreading over a wide area (e.g. by containment or oil<br>barriers).<br>Retain and dispose of contaminated wash water.<br>Local authorities should be advised if significant spillages<br>cannot be contained. |



| Version<br>3.2 | Revision Date:<br>2024/09/28                         | SDS Number:<br>558021-00016  | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15   |  |
|----------------|--|--|---|--|
| -              | thods and materials for<br>ntainment and cleaning up | For large spills,<br>ment to keep ma<br>be pumped, stor<br>Clean up remain<br>bent.<br>Local or nationa<br>posal of this ma<br>employed in the<br>mine which regu<br>Sections 13 and | ert absorbent material.<br>provide dyking or other appropriate contain-<br>aterial from spreading. If dyked material can<br>re recovered material in appropriate container.<br>hing materials from spill with suitable absor-<br>I regulations may apply to releases and dis-<br>terial, as well as those materials and items<br>cleanup of releases. You will need to deter-<br>ulations are applicable.<br>I 15 of this SDS provide information regarding<br>hational requirements. |  |
| 7. HAN         | DLING AND STORAGE                                    |  |   |  |
| Te             | chnical measures                                     |  | g measures under EXPOSURE<br>RSONAL PROTECTION section.   |  |
| Lo             | cal/Total ventilation                                |  | dequate ventilation.  |  |
| Ad             | vice on safe handling                                | : Handle in accord<br>practice, based<br>sessment  | dance with good industrial hygiene and safety<br>on the results of the workplace exposure as-<br>event spills, waste and minimize release to the  |  |
| Co             | nditions for safe storage                            |  | / labelled containers.  |  |
| Ma             | terials to avoid                                     | Store in accordance with the particular national regulation<br>: Do not store with the following product types:<br>Strong oxidizing agents   |   |  |

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

|            | · · · · · · · · · · · · ·      |                                     |  |          |
|------------|--------------------------------|-------------------------------------|--|----------|
| Components | CAS-No.                        | Value type<br>(Form of<br>exposure) | Control parame-<br>ters / Permissible<br>concentration | Basis    |
| Tafluprost | 209860-87-7                    | TWA                                 | 0.002 μg/m3<br>(OEB 5)                                 | Internal |
|            | Further information: Skin, Eye |                                     |  |          |
|            |                                | Wipe limit                          | 0.02 µg/100 cm <sup>2</sup>                            | Internal |

### Components with workplace control parameters

| Engineering measures | : | Use closed processing systems or containment technologies<br>to control at source (e.g., glove boxes/isolators) and to pre-<br>vent leakage of compounds into the workplace.<br>All engineering controls should be implemented by facility<br>design and operated in accordance with GMP principles to<br>protect products, workers, and the environment.<br>No open handling permitted. |
|----------------------|---|--|
|                      |   | Totally enclosed processes and materials transport systems   |



| Version<br>3.2 | Revision Date: 2024/09/28 | SDS Number:<br>558021-00016   | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15   |
|----------------|---------------------------|---|---|
|                |                           |   | quire the use of appropriate containment tech<br>ed to prevent leakage of compounds into the  |
| Perso          | onal protective equip     | ment  |   |
| Resp           | iratory protection        | : If adequate lo sure assessm   | cal exhaust ventilation is not available or expo<br>ent demonstrates exposures outside the rec-<br>lidelines, use respiratory protection.<br>ur type  |
|                | protection                | <b>c</b> ,  |   |
| Ma             | aterial                   | : Chemical-resi   | stant gloves  |
|                | emarks<br>protection      | If the work en<br>mists or aeros<br>Wear a faces  | ble gloving.<br>lasses with side shields or goggles.<br>vironment or activity involves dusty conditions<br>cols, wear the appropriate goggles.<br>hield or other full face protection if there is a<br>frect contact to the face with dusts, mists, or  |
| Skin a         | and body protection       | : Work uniform<br>Additional boo<br>task being per<br>posable suits)  | or laboratory coat.<br>ly garments should be used based upon the<br>formed (e.g., sleevelets, apron, gauntlets, dis<br>to avoid exposed skin surfaces.<br>te degowning techniques to remove potentiall<br>clothing.   |
| Hygie          | ene measures              | : If exposure to<br>eye flushing s<br>ing place.<br>When using d<br>Wash contam<br>The effective<br>engineering co<br>appropriate de<br>industrial hygi | chemical is likely during typical use, provide<br>ystems and safety showers close to the work-<br>o not eat, drink or smoke.<br>inated clothing before re-use.<br>operation of a facility should include review of<br>pontrols, proper personal protective equipment,<br>egowning and decontamination procedures,<br>ene monitoring, medical surveillance and the<br>strative controls. |

| Appearance                   | : | Aqueous solution  |
|------------------------------|---|-------------------|
| Colour                       | : | clear             |
| Odour                        | : | No data available |
| Odour Threshold              | : | No data available |
| рН                           | : | No data available |
| Melting point/freezing point | : | No data available |



## **Tafluprost Formulation**

| Versior<br>3.2 | n Revision Date:<br>2024/09/28                  |   | S Number:<br>021-00016 | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15 |
|----------------|---|---|------------------------|---|
|                |   |   |                        |   |
|                | tial boiling point and boiling<br>nge           | : | No data available      |   |
| Fla            | ash point                                       | : | No data available      | )   |
| E٧             | aporation rate                                  | : | No data available      | )   |
| Fla            | ammability (solid, gas)                         | : | Not applicable         |   |
| Fla            | ammability (liquids)                            | : | No data available      | 9   |
|                | oper explosion limit / Upper<br>mmability limit | : | No data available      | )   |
|                | wer explosion limit / Lower<br>mmability limit  | : | No data available      |   |
| Va             | pour pressure                                   | : | No data available      | )   |
| Re             | elative vapour density                          | : | No data available      | )   |
| Re             | elative density                                 | : | No data available      | 9   |
| De             | ensity  | : | No data available      | 9   |
| So             | lubility(ies)<br>Water solubility               | : | No data available      | 9   |
|                | artition coefficient: n-                        | : | No data available      | )   |
|                | tanol/water<br>Ito-ignition temperature         | : | No data available      | )   |
| De             | ecomposition temperature                        | : | No data available      | 9   |
| Vi             | scosity<br>Viscosity, kinematic                 | : | No data available      | 9   |
| Ex             | plosive properties                              | : | Not explosive          |   |
| O              | kidizing properties                             | : | The substance or       | r mixture is not classified as oxidizing.                         |
| M              | blecular weight                                 | : | No data available      | )   |
|                | article characteristics<br>article size         | : | No data available      | )   |

### **10. STABILITY AND REACTIVITY**

| Reactivity                     | : | Not classified as a reactivity hazard.  |
|--------------------------------|---|---|
| Chemical stability             | : | Stable under normal conditions.         |
| Possibility of hazardous reac- | : | Can react with strong oxidizing agents. |



| /ersion<br>3.2                  | Revision Date: 2024/09/28  |      | S Number:<br>8021-00016                                | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15 |
|---------------------------------|--|------|--|---|
| Incom                           | tions to avoid<br>patible materials<br>dous decomposition<br>cts | :    | None known.<br>Oxidizing ager<br>No hazardous          | its<br>decomposition products are known.                          |
| 1. TOXIC                        | OLOGICAL INFORMAT  | 101  | 1  |   |
| Inform<br>expos                 | nation on likely routes of<br>sure                               | :    | Inhalation<br>Skin contact<br>Ingestion<br>Eye contact |   |
|                                 | e toxicity   |      |  |   |
|                                 | assified based on availa   | ble  | information.   |   |
|                                 | oonents:   |      |  |   |
| <b>Taflu</b><br>Acute           | oral toxicity  | :    | LD50 (Rat): 665  | 5 mg/kg   |
|                                 |  |      | LD50 (Rat): > 1<br>Remarks: No m                       | 00 mg/kg<br>ortality observed at this dose.                       |
|                                 | toxicity (other routes of<br>istration)                          | :    |  | ite: Intravenous<br>Cardio-vascular system                        |
| -                               | corrosion/irritation<br>assified based on availa                 | ble  | information.   |   |
|                                 | us eye damage/eye irri<br>assified based on availa               |      |  |   |
| Comp                            | oonents:   |      |  |   |
| <b>Tafluj</b><br>Speci<br>Resul | es   | :    | Monkey<br>No eye irritatior                            | 1   |
| Resp                            | iratory or skin sensitis   | atio | n  |   |
|                                 | sensitisation<br>assified based on availa                        | ble  | information.   |   |
| -                               | iratory sensitisation<br>assified based on availa                | ble  | information.   |   |
| Comp                            | oonents:   |      |  |   |
| <b>Taflu∣</b><br>Test∃<br>Expos |  | :    | Maximisation T<br>Dermal                               | est   |



|  | Revision Date:<br>2024/09/28  |                       | DS Number:<br>8021-00016   | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15             |
|--|---|-----------------------|--|---|
| Speci<br>Resul   |   | :                     | Guinea pig<br>Not a skin sensi   | tizer.  |
|  | <b>cell mutagenicity</b><br>lassified based on avai   | ilable                | information.   |   |
| <u>Comp</u>  | oonents:  |                       |  |   |
| Taflu  | prost:  |                       |  |   |
| Geno   | toxicity in vitro   | ÷                     | Test Type: Bact<br>Result: negative  | erial reverse mutation assay (AMES)   |
|  |   |                       | Test Type: Chro<br>Result: negative  | mosome aberration test in vitro   |
| Geno   | toxicity in vivo  | :                     | cytogenetic ass<br>Species: Mouse  | te: Intraperitoneal injection   |
|  |   |                       | Result. Regulive   |   |
| Not cl   | <b>nogenicity</b><br>lassified based on avai<br><u>ponents:</u>   | ilable                | -  |   |
| Not cl   | lassified based on avai   | ilable                | -  |   |
| Not cl<br><u>Comp</u><br>Taflu<br>Speci<br>Applic  | lassified based on avai<br>ponents:<br>prost:<br>les<br>cation Route<br>sure time   | ilable<br>:<br>:      | -  |   |
| Not cl<br><u>Comp</u><br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Speci   | lassified based on avai<br><u>ponents:</u><br>prost:<br>res<br>cation Route<br>sure time<br>lt  | ilable<br>:<br>:<br>: | information.<br>Rat<br>Subcutaneous<br>24 Months   |   |
| Not cl<br>Comp<br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Speci<br>Applic  | lassified based on avai<br><u>ponents:</u><br>prost:<br>les<br>cation Route<br>sure time<br>lt<br>les<br>cation Route<br>sure time  | ilable                | information.<br>Rat<br>Subcutaneous<br>24 Months<br>negative<br>Mouse  |   |
| Not cl<br>Comp<br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Speci<br>Applic<br>Expos<br>Resul<br>Repro                   | lassified based on avai<br><u>ponents:</u><br>prost:<br>les<br>cation Route<br>sure time<br>lt<br>lt<br>cation Route<br>sure time<br>sure time<br>lt<br>bductive toxicity                     |                       | information.<br>Rat<br>Subcutaneous<br>24 Months<br>negative<br>Mouse<br>Subcutaneous<br>18 Months<br>negative   |   |
| Not cl<br>Comp<br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Speci<br>Applic<br>Expos<br>Resul<br>Repro<br>Not cl         | lassified based on available<br>prost:<br>les<br>cation Route<br>sure time<br>lt<br>lt<br>cation Route<br>sure time<br>sure time<br>lt<br>but<br>but<br>but<br>but<br>but<br>but<br>but<br>bu |                       | information.<br>Rat<br>Subcutaneous<br>24 Months<br>negative<br>Mouse<br>Subcutaneous<br>18 Months<br>negative   |   |
| Not cl<br>Comp<br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Speci<br>Applic<br>Expos<br>Resul<br>Repro<br>Not cl<br>Comp | lassified based on avai<br><u>ponents:</u><br>prost:<br>les<br>cation Route<br>sure time<br>lt<br>cation Route<br>sure time<br>lt<br>oductive toxicity<br>lassified based on avai<br>ponents: |                       | information.<br>Rat<br>Subcutaneous<br>24 Months<br>negative<br>Mouse<br>Subcutaneous<br>18 Months<br>negative   |   |
| Not cl<br>Comp<br>Taflu<br>Speci<br>Applic<br>Expos<br>Resul<br>Repro<br>Not cl<br>Comp<br>Taflu                             | lassified based on available<br>prost:<br>les<br>cation Route<br>sure time<br>lt<br>lt<br>cation Route<br>sure time<br>sure time<br>lt<br>but<br>but<br>but<br>but<br>but<br>but<br>but<br>bu |                       | information.<br>Rat<br>Subcutaneous<br>24 Months<br>negative<br>Mouse<br>Subcutaneous<br>18 Months<br>negative<br>information.<br>Test Type: Ferti<br>Species: Rat | lity/early embryonic development<br>te: Intravenous injection<br>.: 100 μg/kg |



| Version<br>3.2 | Revision Date:<br>2024/09/28    |   | DS Number:<br>8021-00016                                 | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15                                      |
|----------------|---------------------------------|---|--|--|
|                |                                 |   |  |  |
|                |                                 |   | Developmental To   | e: Intravenous injection<br>oxicity: LOAEL: 10 μg/kg<br>tions were observed., Reduced foetal weight    |
|                |                                 |   | Species: Rat<br>Application Route                        | vo-foetal development<br>: Intravenous injection<br>oxicity: NOAEL: 3 μg/kg                            |
|                |                                 |   | Species: Rabbit<br>Application Route<br>Developmental To | vo-foetal development<br>: Intravenous injection<br>oxicity: LOAEL: 0.03 μg/kg<br>tions were observed. |
|                |                                 |   | Species: Rabbit<br>Application Route                     | vo-foetal development<br>: Intravenous injection<br>oxicity: NOAEL: 0.01 μg/kg                         |
|                |                                 |   | Species: Rat<br>Application Route                        | vo-foetal development<br>: Intravenous injection<br>oxicity: LOAEL: 1 μg/kg                            |
|                |                                 |   | Species: Rat<br>Application Route                        | vo-foetal development<br>: Intravenous injection<br>oxicity: NOAEL: 0.3 μg/kg                          |
| Repro<br>sessr | oductive toxicity - As-<br>nent | : | Clear evidence of animal experimer                       | adverse effects on development, based on<br>ts.  |

### STOT - single exposure

Not classified based on available information.

### Components:

#### Tafluprost:

| Target Organs | : | Lungs, Cardio-vascular system |
|---------------|---|-------------------------------|
| Assessment    | : | Causes damage to organs.      |

### STOT - repeated exposure

Not classified based on available information.

### **Components:**

| Tafluprost:                 |   |
|-----------------------------|---|
| Target Organs<br>Assessment | Lungs, Cardio-vascular system<br>Causes damage to organs through prolonged or repeated<br>exposure. |



|  | Revision Date:<br>2024/09/28   | SDS Number:<br>558021-00016   | Date of last issue: 2023/09/30<br>Date of first issue: 2016/03/15 |
|--|--|---|---|
| -  | ated dose toxicity<br>conents:   |   |   |
|  | prost:   |   |   |
| Speci<br>LOAE<br>Applic<br>Expos   | es   | : Rat<br>: 0.01 mg/kg<br>: Intravenous<br>: 6 Months<br>: Cardio-vascula<br>spleen                                | ar system, Blood, Bone marrow, Kidney, Live                       |
| Expos  | EL<br>EL<br>cation Route<br>sure time<br>et Organs   | : Dog<br>: 0.0001 mg/kg<br>: 0.001 mg/kg<br>: Intravenous<br>: 39 Weeks<br>: Cardio-vascula<br>: Dilatation of th |   |
|  | lassified based on ava<br>rience with human e  |   |   |
| Expe<br><u>Com</u> t<br>Taflu  |  | exposure  | yness of the eyes, Blurred vision                                 |
| Expe<br>Comp<br>Taflu<br>Eye c   | rience with human e<br>ponents:<br>prost:<br>contact<br>OGICAL INFORMAT  | exposure<br>: Symptoms: dry   | yness of the eyes, Blurred vision                                 |
| Expe<br>Comp<br>Taflu<br>Eye c<br>ECOLO<br>ECOLO<br>No da<br>Persi<br>No da  | rience with human e<br>ponents:<br>prost:<br>contact   | xposure<br>: Symptoms: dry  | vness of the eyes, Blurred vision                                 |
| Expe<br>Comp<br>Taflu<br>Eye c<br>ECOLO<br>ECOLO<br>No da<br>Persi<br>No da<br>Bioac   | rience with human e<br>ponents:<br>prost:<br>contact<br>OGICAL INFORMATI<br>oxicity<br>ata available<br>stence and degrada<br>ata available  | xposure<br>: Symptoms: dry  | vness of the eyes, Blurred vision                                 |
| Experience<br>Comp<br>Taflu<br>Eye c<br>ECOLO<br>ECOLO<br>Ecoto<br>No da<br>Persi<br>No da<br>Bioac<br>Comp<br>Taflu<br>Partiti                          | rience with human e<br>ponents:<br>prost:<br>contact<br>OGICAL INFORMATI<br>oxicity<br>ata available<br>stence and degrada<br>ata available<br>ccumulative potentia  | xposure<br>: Symptoms: dry  | vness of the eyes, Blurred vision                                 |
| Experience<br>Comp<br>Taflu<br>Eye control<br>ECOLO<br>ECOLO<br>Ecoto<br>No da<br>Persi<br>No da<br>Bioaco<br>Comp<br>Taflu<br>Partiti<br>octan<br>Mobil | rience with human e<br>ponents:<br>prost:<br>contact<br>OGICAL INFORMATI<br>oxicity<br>ata available<br>stence and degrada<br>ata available<br>ccumulative potentia<br>ponents:<br>prost:<br>ion coefficient: n- | : Symptoms: dry<br>ION<br>bility  | ness of the eyes, Blurred vision                                  |



| Version | Revision Date: | SDS Number:  | Date of last issue: 2023/09/30  |
|---------|----------------|--------------|---------------------------------|
| 3.2     | 2024/09/28     | 558021-00016 | Date of first issue: 2016/03/15 |

### **13. DISPOSAL CONSIDERATIONS**

| Disposal methods       |   |  |
|------------------------|---|--|
| Waste from residues    | : | Do not dispose of waste into sewer.<br>Dispose of in accordance with local regulations.  |
| Contaminated packaging | : | Empty containers should be taken to an approved waste han-<br>dling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product. |

### 14. TRANSPORT INFORMATION

#### **International Regulations**

| international regulations  |   |  |
|--|---|--|
| <b>UNRTDG</b><br>UN number<br>Proper shipping name<br>Class<br>Subsidiary risk<br>Packing group<br>Labels<br>Environmentally hazardous   |   | Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>no             |
| IATA-DGR<br>UN/ID No.<br>Proper shipping name<br>Class<br>Subsidiary risk<br>Packing group<br>Labels<br>Packing instruction (cargo<br>aircraft)<br>Packing instruction (passen-<br>ger aircraft) |   | Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>Not applicable<br>Not applicable |
| <b>IMDG-Code</b><br>UN number<br>Proper shipping name<br>Class   | : | Not applicable<br>Not applicable<br>Not applicable   |

| • | not applicable |
|---|----------------|
| : | Not applicable |
|   |                |

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code** Not applicable for product as supplied.

#### Special precautions for user

Not applicable



| Version | Revision Date: | SDS Number:  | Date of last issue: 2023/09/30  |
|---------|----------------|--------------|---------------------------------|
| 3.2     | 2024/09/28     | 558021-00016 | Date of first issue: 2016/03/15 |

### **15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

| Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances |
|--|
| Hazardous to Health  |

| Hazardous substances that must be registered | : | Not applicable |
|--|---|----------------|
|--|---|----------------|

#### Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

| Hazardous substances approved for use | : | Glycerine      |
|---------------------------------------|---|----------------|
| Prohibited substances                 | : | Not applicable |
| Restricted substances                 | : | Not applicable |

# Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and : Not applicable control, Annex I

Type of hazardous materials subject to distribution and : Not applicable control, Annex II

### The components of this product are reported in the following inventories:

| AICS  | : | not determined |
|-------|---|----------------|
| DSL   | : | not determined |
| IECSC | : | not determined |

#### **16. OTHER INFORMATION**

| Revision Date   | : | 2024/09/28   |
|---|---|--|
| Further information   |   |  |
| Sources of key data used to<br>compile the Safety Data<br>Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/ |
| Date format   | : | yyyy/mm/dd   |

Full text of other abbreviations



| Version | Revision Date: | SDS Number:  |
|---------|----------------|--------------|
| 3.2     | 2024/09/28     | 558021-00016 |

Date of last issue: 2023/09/30 Date of first issue: 2016/03/15

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN